Drug research

GWP42003-P

Open a linked trial to see its study details and recorded changes, or check the regulatory events below and follow their sources.

Drug identity checked against registry records

Also recorded as CBD-OS; Cannabidiol; Cannabidiol oral solution (CBD-OS); EPIDIOLEX; Epidiolex; Epidiolex®; Epidyolex; cannabidiol

A drug appearing in a clinical trial does not mean it is FDA-approved. Check the original regulatory source for any approval claim.

Included trials

Trial	Sponsor	Phase	Status	Primary completion
Efficacy and Safety of GWP42003-P Oral Solution in Children With Epilepsy With Myoclonic-atonic SeizuresNCT05288283	Jazz Pharmaceuticals	Phase 3	Terminated	2023-09-28Actual
Trial to Investigate the Safety and Efficacy of Cannabidiol Oral Solution (GWP42003-P; CBD-OS) in Children and Adolescents With Autism Spectrum DisorderNCT04745026	Jazz Pharmaceuticals	Phase 2	Completed	2023-12-21Actual
Assessment of Adjunctive Cannabidiol Oral Solution (GWP42003-P) in Children With Tuberous Sclerosis Complex (TSC), Dravet Syndrome (DS), or Lennox-Gastaut Syndrome (LGS) Who Experience Inadequately-controlled SeizuresNCT04485104	Jazz Pharmaceuticals	Phase 3	Terminated	2025-01-28Actual
Trial to Investigate the Safety and Efficacy of GWP42003-P Versus Placebo as Adjunctive Therapy in Participants With Schizophrenia Experiencing Inadequate Response to Ongoing Antipsychotic TreatmentNCT04421456	Jazz Pharmaceuticals	Phase 2	Terminated	2022-03-16Actual

Jazz PharmaceuticalsTerminatedPrimary completion: 2023-09-28 · Actual

Trial details

Jazz PharmaceuticalsCompletedPrimary completion: 2023-12-21 · Actual

Trial details

Jazz PharmaceuticalsTerminatedPrimary completion: 2025-01-28 · Actual

Trial details

Jazz PharmaceuticalsTerminatedPrimary completion: 2022-03-16 · Actual

Trial details

No regulatory events match this view.Try another date range or view. Events appear after automated source checks. This does not mean no FDA events have occurred. Dates that a source does not disclose stay undisclosed.